164 related articles for article (PubMed ID: 38710798)
1. Gefitinib metabolism-related lncRNAs for the prediction of prognosis, tumor microenvironment and drug sensitivity in lung adenocarcinoma.
Guo Z; Zhang X; Yang D; Hu Z; Wu J; Zhou W; Wu S; Zhang W
Sci Rep; 2024 May; 14(1):10348. PubMed ID: 38710798
[TBL] [Abstract][Full Text] [Related]
2. The necroptosis-related signature and tumor microenvironment immune characteristics associated with clinical prognosis and drug sensitivity analysis in stomach adenocarcinoma.
Yang B; Wang Y; Liu T; Zhang M; Luo T
Aging (Albany NY); 2024 Mar; 16(7):6098-6117. PubMed ID: 38546403
[TBL] [Abstract][Full Text] [Related]
3. An exosomes-related lncRNA prognostic model correlates with the immune microenvironment and therapy response in lung adenocarcinoma.
Chu D; Chen L; Li W; Zhang H
Clin Exp Med; 2024 May; 24(1):104. PubMed ID: 38761234
[TBL] [Abstract][Full Text] [Related]
4. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD.
Ma C; Gu Z; Yang Y
J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237
[TBL] [Abstract][Full Text] [Related]
5. N-6 methylation-related lncRNA is potential signature in lung adenocarcinoma and influences tumor microenvironment.
Zheng J; Zhao Z; Wan J; Guo M; Wang Y; Yang Z; Li Z; Ming L; Qin Z
J Clin Lab Anal; 2021 Nov; 35(11):e23951. PubMed ID: 34558724
[TBL] [Abstract][Full Text] [Related]
6. A tumor microenvironment-related mRNA-ncRNA signature for prediction early relapse and chemotherapeutic sensitivity in early-stage lung adenocarcinoma.
Gao Z; Han H; Zhao Y; Yuan H; Zheng S; Zhang Y; Chen H
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3195-3209. PubMed ID: 34291356
[TBL] [Abstract][Full Text] [Related]
7. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L
Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150
[TBL] [Abstract][Full Text] [Related]
9. A novel risk model of three gefitinib-related genes FBP1, SBK1 and AURKA is related to the immune microenvironment and is predicting prognosis of lung adenocarcinoma patients.
Guo Q; Li K; Jiang N; Zhou R; Rao XR; Wu CY
Aging (Albany NY); 2023 Sep; 15(18):9633-9660. PubMed ID: 37737707
[TBL] [Abstract][Full Text] [Related]
10. Mitochondria-related lncRNAs: predicting prognosis, tumor microenvironment and treatment response in lung adenocarcinoma.
Zhou Q; Xiong J; Gao Y; Yi R; Xu Y; Chen Q; Wang L; Chen Y
Funct Integr Genomics; 2023 Oct; 23(4):323. PubMed ID: 37864709
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value and immune landscapes of immunogenic cell death-associated lncRNAs in lung adenocarcinoma.
Shu K; Cai C; Chen W; Ding J; Guo Z; Wei Y; Zhang W
Sci Rep; 2023 Nov; 13(1):19151. PubMed ID: 37932413
[TBL] [Abstract][Full Text] [Related]
12. Immune- and Stemness-Related Genes Revealed by Comprehensive Analysis and Validation for Cancer Immunity and Prognosis and Its Nomogram in Lung Adenocarcinoma.
Chen M; Wang X; Wang W; Gui X; Li Z
Front Immunol; 2022; 13():829057. PubMed ID: 35833114
[TBL] [Abstract][Full Text] [Related]
13. Identifying a lactic acid metabolism-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma.
Zhao F; Wang Z; Li Z; Liu S; Li S
Front Immunol; 2022; 13():980508. PubMed ID: 36275729
[TBL] [Abstract][Full Text] [Related]
14. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
Liang H; Li Y; Qu Y; Zhang L
Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
[TBL] [Abstract][Full Text] [Related]
15. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
16. Significance of
Lin H; Wang J; Shi Q; Wu M
PeerJ; 2024; 12():e17338. PubMed ID: 38708353
[TBL] [Abstract][Full Text] [Related]
17. Risk stratification of lung adenocarcinoma using a nomogram combined with ferroptosis-related LncRNAs and subgroup analysis with immune and N6-methyladenosine modification.
Gao C; Kong N; Zhang F; Tang T; Li J; Ding H; Sun Z; Wu L; Xu M
BMC Med Genomics; 2022 Jan; 15(1):15. PubMed ID: 35093068
[TBL] [Abstract][Full Text] [Related]
18. [Effect of SLC7A11 gene downregulation on the gefitinib resistance of lung adenocarcinoma PC9/GR cells and its mechanism].
Jia YL; Zhao Y; Zhen SM; Cheng ZS; Zheng BY; Liu YP; Liu LH
Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):779-786. PubMed ID: 37805442
[No Abstract] [Full Text] [Related]
19. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma.
Ren J; Wang A; Liu J; Yuan Q
Bioengineered; 2021 Dec; 12(1):4331-4348. PubMed ID: 34338158
[TBL] [Abstract][Full Text] [Related]
20. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]